Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

388 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, Castiglia M, Rizzo S, Vullo FL, Fiorentino E, Van Meerbeeck J, Russo A. Bronte G, et al. Among authors: rolfo c. Crit Rev Oncol Hematol. 2014 Feb;89(2):300-13. doi: 10.1016/j.critrevonc.2013.08.003. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24041630
Proteomics in cancer research: Are we ready for clinical practice?
Maes E, Mertens I, Valkenborg D, Pauwels P, Rolfo C, Baggerman G. Maes E, et al. Among authors: rolfo c. Crit Rev Oncol Hematol. 2015 Dec;96(3):437-48. doi: 10.1016/j.critrevonc.2015.07.006. Epub 2015 Aug 12. Crit Rev Oncol Hematol. 2015. PMID: 26277237 Review.
On the pharmacogenetics of non-small cell lung cancer treatment.
Santarpia M, Rolfo C, Peters GJ, Leon LG, Giovannetti E. Santarpia M, et al. Among authors: rolfo c. Expert Opin Drug Metab Toxicol. 2016;12(3):307-17. doi: 10.1517/17425255.2016.1141894. Epub 2016 Feb 17. Expert Opin Drug Metab Toxicol. 2016. PMID: 26761638 Review.
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice.
Taverna S, Giallombardo M, Gil-Bazo I, Carreca AP, Castiglia M, Chacártegui J, Araujo A, Alessandro R, Pauwels P, Peeters M, Rolfo C. Taverna S, et al. Among authors: rolfo c. Oncotarget. 2016 May 10;7(19):28748-60. doi: 10.18632/oncotarget.7638. Oncotarget. 2016. PMID: 26919248 Free PMC article. Review.
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica R, de Castro G Jr, Gil-Bazo I, Caglevic C, Calogero R, Giallombardo M, Santos ES, Raez LE, Rolfo C. Caparica R, et al. Among authors: rolfo c. Crit Rev Oncol Hematol. 2016 May;101:32-9. doi: 10.1016/j.critrevonc.2016.02.012. Epub 2016 Feb 27. Crit Rev Oncol Hematol. 2016. PMID: 26960735 Review.
388 results